Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Mar 14, 2024 10:30am
108 Views
Post# 35932570

RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and ChinaMarch 14, 2024 - Trade group Biotechnology Industry Organization (BIO) announced Wednesday that it is cutting ties with WuXi AppTec as the lobby takes steps to “separate” from the China-based biotech from its membership. Wednesday’s decision comes after a congressional committee recently blasted the Biotechnology Industry Organization (BIO) for allegedly lobbying on behalf of WuXi AppTec.

Last week, Rep. Mike Gallagher (R-WI), chairman of the Committee on the Chinese Communist Party, stated that BIO’s lobbying “advances the interest of the Chinese Communist Party” and “raises concerns that it is operating as an unregistered agent of a foreign principal.” 

In addition to separating from WuXi AppTec, BIO will now openly support the BIOSECURE Act and will cooperate with Congress as the legislation progresses.


https://www.biospace.com/article/bio-boots-china-s-wuxi-apptec-from-biotech-trade-group-amid-national-security-concerns/
<< Previous
Bullboard Posts
Next >>